This trial is evaluating whether Ixazomib Citrate will improve 1 primary outcome, 5 secondary outcomes, and 2 other outcomes in patients with Plasma Cell Myeloma. Measurement will happen over the course of The time from registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years.
This trial requires 80 total participants across 1 different treatment group
This trial involves a single treatment. Ixazomib Citrate is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Not only may one's risk increase with age and family history, but also the severity of multiple myeloma may also result from genetics and environmental factors. To prevent, evaluate and treat, one should check if the people with high family risk, have abnormal blood screen (particularly the ALT and lactic dehydrogenase) are suspected for multiple myeloma." - Anonymous Online Contributor
"The cause of multiple myeloma is unknown. This disease is frequently diagnosed at an advanced stage. The most common cause was a previous or current cancer; however this was not statistically different. The most likely causes were exposure to tobacco and environmental factors." - Anonymous Online Contributor
"Around 25,000 people could have multiple myeloma a year. Most individuals get multiple myeloma after the age of 60 years (approximately 70%). Multiple myeloma affects about 1 in 10,000 and 1 in 15,000 live in the United States currently, and most cases are not diagnosed between the ages of 20 and 40 years. Although multiple myeloma is more common in males when compared to females, women are more likely to receive multiple myeloma treatment after the age of 55 years." - Anonymous Online Contributor
"Treatment of MM is often palliative and includes antimetabolite chemotherapy combinations such as bortezomib + dexamethasone, proteasome inhibitors such as bortezomib + lenalidomide, high dose corticosteroid regimens, and immunomodulatory agents such as thalidomide." - Anonymous Online Contributor
"Although several treatment agents have been shown to be effective in the treatment of myeloma in the first-line/conditional/injectable-based treatments are still preferable in the case of refractory disease that is considered a hopeless disease. Long-term survival is associated with remission and overall survival. The best regimen in order to achieve this goal is unclear. However, the presence of myeloma-inhibiting monoclonal antibodies has improved outcomes in these patients." - Anonymous Online Contributor
"More than 50% of multiple myeloma patients have hypercalcaemia. This high prevalence of bone pain and bone pain-associated conditions is a relevant phenomenon. The patients' physical function and quality of life are adversely affected. The patients' condition is not worse during hospitalisation." - Anonymous Online Contributor
"Ixazomib is safe and well tolerated for up to 12 months in patients with myeloma and has shown superiority in terms of OS and PFS compared with historical controls. Ixazomib citrate has now been licensed in Europe and the US." - Anonymous Online Contributor
"The average person diagnosed with MM will die of other causes, typically from cardiovascular disease and lymphoproliferative diseases. Since most people with MM are middle aged or younger, many will not be diagnosed with MM until they reach the age of 70. Because MM is not a lifetime illness, patients and family members should anticipate that the average age of diagnosis of MM will continually rise." - Anonymous Online Contributor
"Ixazomib was effective against patients with MM and was well tolerated, with a high rate of patient satisfaction. Based on these findings, ixazomib appears to show promise as a second-line agent for MM after thalidomide or bortezomib." - Anonymous Online Contributor
"As for other MM treatments, the research is advancing at an ever faster rate. Researchers are working tirelessly on finding safe and effective new therapies for treating patients with MM. The most important advances in this area include: (1) the development of effective new drugs and novel combinations, (2) new therapeutic strategies in the use of HDT to treat MM, and (3) the development of novel non-biologic therapies by combining new drugs with previously existing therapies. In summary, recent advances in MM research provide a glimpse into not only the future of MM treatment, but also the research necessary for finding the most effective treatment options for patients with MM." - Anonymous Online Contributor
"The most common adverse effects with ixazomib citrate in people were dizziness and nausea (30% each), headache (5%), fever (5%), constipation (4%), and fatigue (3%; all ≥1%). These symptoms decreased after the first month. There were no serious adverse events; two deaths occurred; one of these was associated with a previous malignancy. Findings from a recent study is the first to assess the risk management and adverse effects of ixazomib citrate." - Anonymous Online Contributor
"The cause(s) of MM is a contentious issue. The available evidences are inconclusive; thus, it was not possible to definitively identify the cause(s) of the disease. A thorough systematic and conceptual characterization of MMs is lacking and no reliable biomarkers allow a prompt and effective diagnosis." - Anonymous Online Contributor